These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 34063096)

  • 1. Mechanisms of PD-L1 Regulation in Malignant and Virus-Infected Cells.
    Farrukh H; El-Sayes N; Mossman K
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34063096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
    Ai L; Xu A; Xu J
    Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
    Chen J; Jiang CC; Jin L; Zhang XD
    Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
    Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
    J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving the synergistic combination of programmed death-1/programmed death ligand-1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment.
    Mudassar F; Shen H; Cook KM; Hau E
    J Med Imaging Radiat Oncol; 2022 Jun; 66(4):560-574. PubMed ID: 35466515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1/PD-L1 axis regulation in cancer therapy: The role of long non-coding RNAs and microRNAs.
    Ashrafizadeh M; Zarrabi A; Hushmandi K; Zarrin V; Moghadam ER; Zabolian A; Tavakol S; Samarghandian S; Najafi M
    Life Sci; 2020 Sep; 256():117899. PubMed ID: 32504749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
    Wang Y; Ma R; Liu F; Lee SA; Zhang L
    Front Immunol; 2018; 9():374. PubMed ID: 29556232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy.
    Yin S; Chen Z; Chen D; Yan D
    Theranostics; 2023; 13(5):1520-1544. PubMed ID: 37056572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint.
    Wang Q; Lin W; Tang X; Li S; Guo L; Lin Y; Kwok HF
    Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy.
    Shklovskaya E; Rizos H
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32992658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The roles of PD-1/PD-L1 and its signalling pathway in gastrointestinal tract cancers.
    Cui C; Yu B; Jiang Q; Li X; Shi K; Yang Z
    Clin Exp Pharmacol Physiol; 2019 Jan; 46(1):3-10. PubMed ID: 30161295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy.
    Jiang W; Pan S; Chen X; Wang ZW; Zhu X
    Mol Cancer; 2021 Sep; 20(1):116. PubMed ID: 34496886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy.
    Liu K; Sun Q; Liu Q; Li H; Zhang W; Sun C
    Biomed Pharmacother; 2022 Oct; 154():113618. PubMed ID: 36055113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Blockade Mediated by a Small-Molecule Nanoinhibitor Targeting the PD-1/PD-L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer.
    Zhang R; Zhu Z; Lv H; Li F; Sun S; Li J; Lee CS
    Small; 2019 Dec; 15(49):e1903881. PubMed ID: 31702880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1/PD-1 axis as a potent therapeutic target in breast cancer.
    Bastaki S; Irandoust M; Ahmadi A; Hojjat-Farsangi M; Ambrose P; Hallaj S; Edalati M; Ghalamfarsa G; Azizi G; Yousefi M; Chalajour H; Jadidi-Niaragh F
    Life Sci; 2020 Apr; 247():117437. PubMed ID: 32070710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments.
    Jachetti E; Sangaletti S; Chiodoni C; Ferrara R; Colombo MP
    Cell Immunol; 2021 Apr; 362():104301. PubMed ID: 33588246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma.
    Shu C; Li Q
    Crit Rev Oncol Hematol; 2020 Jul; 151():102965. PubMed ID: 32442903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
    Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
    Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.